Y-MABS THERAPEUTICS ($NASDAQ:YMAB) announced their earnings results for the second quarter of fiscal year 2023, which concluded on June 30 2023. Total revenue for the quarter was USD 20.8 million, an impressive 92.1% growth from the same quarter in 2022. Net income for the quarter amounted to USD -6.3 million, representing a massive improvement from the -41.1 million reported in the same period of the prior year.
On Thursday, Y-MABS THERAPEUTICS, a biopharmaceutical company specializing in the development of cancer treatments, reported their financial earnings for the second quarter of fiscal year 2023. The stock opened at $6.0 and closed the day 5.5% higher at $6.2, up from its prior closing price of $5.8. The positive earnings results reflect Y-MABS THERAPEUTICS’ commitment to innovation and excellence in cancer treatments. The company is dedicated to bringing affordable and effective treatments to patients around the world and has made great progress in developing new and improved therapies.
Overall, investors responded positively to the news with the stock appreciating 5.5% from its prior closing price. Y-MABS THERAPEUTICS continues to be a leader in the development of cancer treatments and the strong financial performance for Q2 FY 2023 speaks to their expertise and commitment to success. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Y-mabs Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Y-mabs Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Y-mabs Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Y-mabs Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale’s analysis of Y-MABS THERAPEUTICS reveals that it is a ‘cheetah’ company, meaning that it has achieved strong revenue or earnings growth but may be less stable due to lower profitability. Our star chart shows that Y-MABS THERAPEUTICS is strong in terms of asset and growth, but weak in dividend and profitability. Additionally, our health score for Y-MABS THERAPEUTICS is 4/10, indicating that it may be able to pay off debt and fund future operations. Given the nature of a ‘cheetah’ company, Y-MABS THERAPEUTICS may be of interest to investors who are looking for higher returns with a higher risk as well as those who are looking for an opportunity to capitalize on potential high growth. Investors should keep in mind that there is a potential risk associated with investing in such a company. More…
Risk Rating Analysis
Star Chart Analysis
The company’s lead product candidate, naxitamab, is in clinical development for the treatment of neuroblastoma, a rare and aggressive pediatric cancer. Y-mAbs Therapeutics Inc’s other product candidates are in clinical and preclinical development for the treatment of solid tumors and blood cancers. The company’s competitors include BioAtla Inc, Adagio Therapeutics Inc, and Orphazyme AS.
BioAtla Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immuno-oncology agents. The company’s market cap as of 2022 is 357.65M and its ROE is -41.59%. BioAtla’s main competitors are Bluebird bio, Inc. (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG).
– Adagio Therapeutics Inc ($NASDAQ:ADGI)
Orphazyme AS is a biotech company that focuses on developing treatments for rare diseases. The company has a market cap of 5.88M as of 2022 and a Return on Equity of -845.21%. Despite its negative ROE, Orphazyme AS’s market cap indicates that investors are confident in the company’s future prospects. This is likely due to the fact that Orphazyme AS is working on developing treatments for rare diseases, which is a highly lucrative market.
Y-MABS THERAPEUTICS reported strong second quarter results for FY 2023, with total revenue up 92.1% year-over-year and net income up significantly from the prior year. The stock price responded positively to this news, offering investors an encouraging sign of the company’s financial health. With its innovative drug development pipeline and strong market presence, Y-MABS looks to be an attractive investment opportunity in the healthcare space. Investors should also consider the company’s potential for long-term growth as it continues to build on its successes.